Which biochemical assay is best for measuring diabetes prevalence?  by Makaroff, Lydia E & Cavan, David
Comment
582 www.thelancet.com/diabetes-endocrinology   Vol 3   August 2015
Published Online
June 22, 2015
http://dx.doi.org/10.1016/
S2213-8587(15)00203-X
See Articles page 624 
 Which biochemical assay is best for measuring diabetes 
prevalence?
Accurate assessments of diabetes prevalence are 
needed to allocate resources for treating patients and 
monitoring treatment coverage. Researchers need 
methods of making population-wide assessments of 
diabetes that are cost eﬀ ective, precise, and reliable.
Because up to half of all diabetes cases might be 
undiagnosed,1 one of three biochemical tests are used 
to estimate diabetes prevalence. Fasting plasma glucose 
(FPG) is a measure of glucose concentrations after the 
person has refrained from eating or drinking anything 
other than water for 12 h. The oral glucose tolerance test 
(OGTT) measures the changes in blood glucose after a 
ﬁ xed amount of glucose has been administered. HbA1c 
does not directly measure blood glucose, but represents 
the average amount of glucose in the blood in the 
past 2–3 months.2 The degree to which these diﬀ erent 
measures correlate in diverse geographical and ethnic 
populations has largely been unanswered. 
Now, results from a total of three randomised studies 
that have tested metformin in patients without diabetes 
(MetCAB1, CAMERA7, and GIPS-III8) have not shown an 
eﬀ ect of metformin on cardiovascular outcomes. In 
CAMERA,7 metformin (850 mg twice per day) given 
to 173 patients without diabetes did not result in a 
signiﬁ cant reduction in the primary outcome measure 
of carotid intima-media thickness after 18 months. In 
GIPS-III,8 metformin (500 mg twice per day) given to 
380 patients without diabetes was not associated with 
a signiﬁ cant eﬀ ect on left ventricular ejection fraction 
compared with placebo after 4 months. In our opinion, 
the results from these studies show how far standard 
care for cardiovascular patients without diabetes has 
advanced; as a consequence, the potential beneﬁ t of 
any additional intervention is small. In all three trials the 
mortality rate was very low—in MetCAB,1 all patients 
were alive 30 days after surgery; in CAMERA, only one 
cardiovascular death occurred over an 18-month follow-
up period;7 and in GIPS-III, all patients were alive 4 months 
after acute myocardial infarction.8 Moreover, peak 
troponin I concentrations in all patients in the MetCAB 
trial were only 50% of those in the historical cohort that 
was the basis of the investigators’ power calculation.1 
According to the power calculation, to show any eﬀ ect, 
metformin needed to lower postoperative troponin I 
concentrations by an additional 50%. Thus, the expected 
eﬀ ect of metformin in patients without diabetes treated 
to current standards might have been too high.
Taking together the results of all studies on metformin 
in patients without diabetes so far, no proof exists for a 
beneﬁ cial eﬀ ect of metformin on cardiovascular outcomes. 
Much larger trials—ie, with thousands of high-risk 
patients—might identify protective eﬀ ects of metformin 
in such patients; however, undertaking such large 
investigator-driven studies is extraordinarily challenging. 
Nevertheless, metformin reduces hyperglycaemia in 
patients with or without diabetes, and glucose reduction, 
or the absence of hyperglycaemia, is pivotal for a potential 
beneﬁ cial eﬀ ect of metformin on cardiovascular outcomes. 
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The question of whether these measures give 
comparable results is particularly important when 
comparing data from resource-poor countries. Diabetes 
aﬀ ects an estimated 8·3% of adults (aged 20–79 years) 
worldwide, and varies with geographical region, from 
5·1% in sub-Saharan Africa to 11·4% in North America 
and the Caribbean.1 At present, high quality diabetes 
surveys are available for only 57% of 221 countries and 
territories worldwide, and only 19% of countries have 
OGTT-based results.1 Instead, many countries with 
limited resources use the simple and standardised WHO 
STEPwise approach to Surveillance (STEPS) protocol for 
risk factor surveillance, published in 2005. The STEPS 
core risk factors include demographic information, health 
behaviours, BMI, waist circumference, and blood pressure. 
WHO recommends that well-resourced countries also 
analyse FPG, with an optional module for OGTT.3 
When it was ﬁ rst correlated to FPG in the late 
1970s, HbA1c was unstandardised.4 However, by 2009, 
technology had improved to such a degree that an 
international expert committee appointed by the 
American Diabetes Association, the European Association 
for the Study of Diabetes, and the International Diabetes 
Federation recommended that a standardised HbA1c test 
done in a laboratory could be used to diagnose type 2 
diabetes.5 An HbA1c of 6·5% (48 mmol/mol) or higher 
is diagnostic for diabetes, although a value below this 
threshold does not exclude diabetes.
In The Lancet Diabetes & Endocrinology, the NCD Risk 
Factor Collaboration has done a global meta-analysis of 
various methods of assessing national and subnational 
prevalence of diabetes.6 They concluded that prevalence 
estimates based on FPG only and those based on FPG 
or 2hOGTT had a very strong correlation (r=0·98), and 
HbA1c-based deﬁ nitions had a lower (although still 
strong) correlation (r=0·91) with FPG-based deﬁ nitions. 
Prevalence based on HbA1c was lower than prevalence 
based on FPG in 42·8% of cases and higher in 41·5%. 
HbA1c was less sensitive than FPG only and than FPG 
or 2hOGTT for detecting undiagnosed diabetes. The 
identiﬁ cation of previously undiagnosed diabetes based 
on HbA1c had a pooled speciﬁ city (true negative rate) of 
99·7% and a pooled sensitivity (true positive rate) of 
52·8% compared with FPG, and a sensitivity of 30·5% 
compared with FPG or 2hOGTT.6
These results will aﬀ ect the design of epidemiological 
studies. Researchers should consider resources and 
population characteristics when deciding whether to 
use FPG, OGTT, or HbA1c tests. Testing FPG is faster 
than testing OGTT, and needs less equipment and staﬀ  
training. However, it does require the person to have 
fasted, which cannot be guaranteed. An HbA1c test 
can be done at any time, requires no fasting or glucose 
consumption, and the sample is relatively stable at 
room temperature. However, the HbA1c test must be 
standardised and done in a certiﬁ ed laboratory, and 
cannot be used in a population with a condition that 
changes red blood cell turnover, such as chronic malaria.5 
Furthermore, the NCD Risk Factor Collaboration reported 
that the relation between glucose-based and HbA1c-
based prevalences varied with national income, year of 
study, and BMI.6 This ﬁ nding, together with the reduced 
sensitivity in detecting undiagnosed diabetes, suggests 
that, under existing diagnostic criteria, an HbA1c test 
should be supplemented with a glucose-based test in 
assessments of population-level prevalence.  
Nevertheless, the high degree of correlation reported 
by the NCD Risk Factor Collaboration suggests 
some ﬂ exibility might be possible in using diﬀ erent 
measurement strategies in diﬀ erent contexts, increasing 
the ease of producing a worldwide estimate of present 
and future epidemiological patterns for diabetes.
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